{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:32:53Z","timestamp":1790029973341,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaad.2020.05.007","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T12:30:40Z","timestamp":1589373040000},"page":"1341-1348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study"],"prefix":"10.1016","volume":"83","author":[{"given":"John W.","family":"Frew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Navrazhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sullivan-Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gilleaudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Garcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"56","key":"10.1016\/j.jaad.2020.05.007_bib1","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jaci.2018.01.010","article-title":"Hidradenitis suppurativa as an autoinflammatory keratinization disease","volume":"141","author":"De Vita","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.jaad.2020.05.007_bib2","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.007_bib3","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-Handel","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.05.007_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/bjd.18556","article-title":"Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa","volume":"182","author":"Navrazhina","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.05.007_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nri.2015.2","article-title":"IL-7 receptor composition","volume":"16","author":"Gaffen","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaad.2020.05.007_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.05.007_bib7","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-il-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2020.05.007_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.05.007_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaad.2020.05.007_bib10","series-title":"Common Terminology Criteria for Adverse Events (CTCAE v5.0)","year":"2017"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.007_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.007_bib12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.007_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.007_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.jaad.2020.05.007_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.007_bib16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/bjd.18309","article-title":"Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies","volume":"181","author":"Frew","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.007_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.05.007_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"10.1016\/j.jaad.2020.05.007_bib19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jaad.2020.05.007_bib20","first-page":"166","article-title":"Pain perception in patients with hidradenitis suppurativa","volume":"182","author":"Neilsen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.05.007_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2020.05.007_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","article-title":"Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis","volume":"155","author":"Machado","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.007_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaad.2019.05.065","article-title":"Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: a systematic review","volume":"82","author":"Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.007_bib24","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates and significantly associated covariates are dependent upon choice of outcome measure in hidradenitis suppurativa: a post-hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.007_bib25","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/jdv.15368","article-title":"Guselkumab in the treatment of severe hidradenitis suppurativa","volume":"33","author":"Kovacs","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.007_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2018.12.017","article-title":"Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review","volume":"81","author":"Casseres","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.007_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jdcr.2018.12.002","article-title":"Secukinumab and hidradenitis suppurativa: friends or foes?","volume":"5","author":"Marasca","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.05.007_bib28","doi-asserted-by":"crossref","unstructured":"Odorici G, Pellacani G, Conti A. Ixekizumab in hidradenitis suppurativa: a case report in a psoriatic patient [e-pub ahead of print]. G Ital Dermatol Venereol. https:\/\/doi.org\/10.23736\/S0392-0488.18.06135-7. Accessed June 8, 2020.","DOI":"10.23736\/S0392-0488.18.06135-7"},{"key":"10.1016\/j.jaad.2020.05.007_bib29","unstructured":"Yeung J, Ladda M, Piguet V. Dose optimisation of brodalumab in moderate-to-severe plaque psoriasis. Abstract presented at: 24th World Congress of Dermatology; June 10-15, 2019. Milan, Italy."},{"issue":"1","key":"10.1016\/j.jaad.2020.05.007_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.007_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220308343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220308343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:56:28Z","timestamp":1759272988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220308343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0190962220308343"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.007","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}